UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 51

Sortiert nach

Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: A single center study

Cancer, 2015-04, Vol.121 (7), p.1064-1070

2015

Volltextzugriff (PDF)

Rapid Immune Recovery and Graft-versus-Host Disease–like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells

Clinical cancer research, 2009-07, Vol.15 (13), p.4499-4507

2009

Volltextzugriff (PDF)

93 - Made Us Stronger

Transplantation and cellular therapy, 2023-02, Vol.29 (2), p.S76-S77

2023

Volltextzugriff (PDF)

Made Us Stronger

Transplantation and cellular therapy, 2023-02, Vol.29 (2), p.S76-S77

2023

Volltextzugriff (PDF)

105 - Improving Productivity and Monitoring: Utilization of Dashboard Technology for Continuous Process Improvement Forms

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S89-S90

2022

Volltextzugriff (PDF)

Improving Productivity and Monitoring: Utilization of Dashboard Technology for Continuous Process Improvement Forms

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S89-S90

2022

Volltextzugriff (PDF)

Rapid relapse of large B‐cell lymphoma after CD19 directed CAR‐T‐cell therapy due to CD‐19 antigen loss

American journal of hematology, 2019-10, Vol.94 (10), p.E273-E275

2019

Volltextzugriff (PDF)

Impaired mRNA Based COVID-19 Vaccine Response in Patients with B-Cell Malignancies after CD19 Directed CAR-T Cell Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.1738-1738

2021

Volltextzugriff (PDF)

Sublingual Microcirculatory Imaging As a Novel Tool to Monitor for Cytokine Release Syndrome after Chimeric Antigen Receptor T-Cell Therapy

Blood, 2018-11, Vol.132 (Supplement 1), p.5408-5408

2018

Volltextzugriff (PDF)

Chimeric antigen receptor T‐cell therapy after allogeneic stem cell transplant for relapsed/refractory large B‐cell lymphoma

British journal of haematology, 2021-01, Vol.192 (1), p.212-216

2021

Volltextzugriff (PDF)

Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

Clinical cancer research, 2014-03, Vol.20 (5), p.1355-1365

2014

Volltextzugriff (PDF)

Monthly Internal Assessments Result in Successful CIBMTR Audit

Biology of blood and marrow transplantation, 2015-02, Vol.21 (2), p.S264-S265

2015

Volltextzugriff (PDF)

Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell Lymphoma with a Day 28 Partial Response By PET/CT Imaging Following CAR-T Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.3876-3876

2021

Volltextzugriff (PDF)

The impact of bridging therapy prior to CD19‐directed chimeric antigen receptor T‐cell therapy in patients with large B‐cell lymphoma

British journal of haematology, 2021-11, Vol.195 (3), p.405-412

2021

Volltextzugriff (PDF)

Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab

American journal of hematology, 2019-08, Vol.94 (8), p.E216-E219

2019

Volltextzugriff (PDF)

The Process of Choosing the Best Match for BMT Informatics Software

Biology of blood and marrow transplantation, 2016-03, Vol.22 (3), p.S299-S299

2016

Volltextzugriff (PDF)

Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier

Blood, 2019-11, Vol.134 (Supplement_1), p.4454-4454

2019

Volltextzugriff (PDF)

Early imaging biomarker assessment to predict long-term responses for large B-cell lymphoma (LBCL) after CAR-T therapy

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7560-7560

2019

Volltextzugriff (PDF)

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes

Blood, 2019-11, Vol.134 (Supplement_1), p.3239-3239

2019

Volltextzugriff (PDF)

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer

Nature medicine, 2005-11, Vol.11 (11), p.1230-1237

2005

Volltextzugriff (PDF)

Transplant Center Survey of CIBMTR Internal Assessments

Biology of blood and marrow transplantation, 2014-02, Vol.20 (2), p.S207-S207

2014

Volltextzugriff (PDF)

Outcome Comparison of Lymphoma and Myeloma Patients after Autologous Stem Cell Transplantation (ASCT) with Peripheral Blood Stem Cell Mobilization Between Plerixafor (P) Mobilized in Poor Mobilizer Patients and Non-Plerixafor Mobilized Patients

Blood, 2015-12, Vol.126 (23), p.5507-5507

2015

Volltextzugriff (PDF)

Stem Cell Infusion Education: A Creative Approach

Biology of blood and marrow transplantation, 2016-03, Vol.22 (3), p.S464-S464

2016

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: A single center study

Rapid Immune Recovery and Graft-versus-Host Disease–like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells

93 - Made Us Stronger

Made Us Stronger

105 - Improving Productivity and Monitoring: Utilization of Dashboard Technology for Continuous Process Improvement Forms

Improving Productivity and Monitoring: Utilization of Dashboard Technology for Continuous Process Improvement Forms

Rapid relapse of large B‐cell lymphoma after CD19 directed CAR‐T‐cell therapy due to CD‐19 antigen loss

Impaired mRNA Based COVID-19 Vaccine Response in Patients with B-Cell Malignancies after CD19 Directed CAR-T Cell Therapy

Sublingual Microcirculatory Imaging As a Novel Tool to Monitor for Cytokine Release Syndrome after Chimeric Antigen Receptor T-Cell Therapy

Chimeric antigen receptor T‐cell therapy after allogeneic stem cell transplant for relapsed/refractory large B‐cell lymphoma

Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

Long-Term Outcomes of Busulfan, Fludarabine and 400 Cgy Total Body Irradiation Versus Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Hematologic Diseases: A Large Single Center Experience

Monthly Internal Assessments Result in Successful CIBMTR Audit

Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell Lymphoma with a Day 28 Partial Response By PET/CT Imaging Following CAR-T Therapy

The impact of bridging therapy prior to CD19‐directed chimeric antigen receptor T‐cell therapy in patients with large B‐cell lymphoma

Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab

The Process of Choosing the Best Match for BMT Informatics Software

Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier

Early imaging biomarker assessment to predict long-term responses for large B-cell lymphoma (LBCL) after CAR-T therapy

Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center Experience

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer

Transplant Center Survey of CIBMTR Internal Assessments

Outcome Comparison of Lymphoma and Myeloma Patients after Autologous Stem Cell Transplantation (ASCT) with Peripheral Blood Stem Cell Mobilization Between Plerixafor (P) Mobilized in Poor Mobilizer Patients and Non-Plerixafor Mobilized Patients

Stem Cell Infusion Education: A Creative Approach

Suchergebnisse filtern